Efficacy of a half dose of oral pyridostigmine in the treatment of chronic fatigue syndrome: Three case reports

Pathophysiology

Volumn 9, Issue 3, 2003, Pages 189-194

  Kawamura, Yasuo ^a   Kihara, Mikihiro ^b   Nishimoto, Kazuhiro ^b   Taki, Mayumi ^a  

^a Kawamura Hospital   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Cholinergic; Chronic fatigue syndrome; Dysautonomia; Neuromuscular; Oral pyridostigmine

Indexed keywords

IMMUNOGLOBULIN G; PYRIDOSTIGMINE;

ABDUCTOR POLLICIS BREVIS MUSCLE; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC FATIGUE SYNDROME; DIAGNOSTIC TEST; DRUG EFFICACY; ELECTROMYOGRAPHY; EPSTEIN BARR VIRUS; FEMALE; HAND MUSCLE; HUMAN; MUSCLE ACTION POTENTIAL; NERVE STIMULATION; NEUROMUSCULAR TRANSMISSION; PRIORITY JOURNAL; SEROLOGY; TREATMENT OUTCOME;

EID: 0142059279     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4680(03)00007-5     Document Type: Article

References (35)

1. Sharpe M. Doctors' diagnoses and patients perceptions: lessons from chronic fatigue syndrome. Gen. Hosp. Psychiatry. 20:1998;335-338.
2. Deal A., Wessely S. Patient's perceptions of medical care in chronic fatigue syndrome. Soc. Sci. Med. 52:2001;1859-1864.
3. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. International chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann. Intern. Med. 121:1994;953-959.
4. Prins J.B., Bleijenberg G. Cognitive behavior therapy for chronic fatigue syndrome: a case study. J. Behav. Ther. Exp. Psychiatry. 30:1999;325-339.
5. Wilson A., Hickie I., Lloyd A., Hadzi-Pavlovic D., Boughton C., Dweyer J., Wakefield D. Longitudinal study of outcome of chronic fatigue syndrome. Br. Med. J. 308:1994;756-759.
6. Vercoulen J.H.M.M., Swanink C.M.A., Galama J.M.P., Fennits J.F.M., van der Meer J.W.M., Bleijenderg G. Prognosis in chronic fatigue syndrome (CFS): a prospective study on the natural course. J. Neurol. Neurosurg. Psychiatry. 60:1996;489-494.
7. Vercoulen J.H.M.M., Swanink C.M.A., Zitmann F.G., Vreden S.G.S., Hoofs M.P.E., Fennis J.F.M., Galama J.M.D., van der Meer J.W.M., Bleijenberg G. A randomized placebo-controlled, double-blind study of fluoxetine in chronic fatigue syndrome. Lancet. 347:1996;858-861.
8. Dyck D., Allen S., Barron J., Marchi J., Price B.A., Spavor J., Kinesiology B.S., Tateishi S. Management of chronic fatigue syndrome. AAOHNJ. 44:1996;85-162.
9. Oh S. Electromyography. 1988;87-109 Williams and Wilkins, Baltimore, MD.
10. Oh S.J. 8-10% decremental response is not the normal limit for all muscles: Seventh International Conference on Myasthenia Gravis. Ann. NY Acad. Sci. 505:1987;851-853.
11. Sandroni P., Ahlskog J.E., Fearley R.D., Low P.A. Autonomic involvement in extra pyramidal and cerebellar disorders. Clin. Auton. Res. 1:1991;147-155.
12. Kihara M., Mitsui M., Nishikawa S., Nishimoto K., Takahashi M. Comparison of electrophysiologic and autonomic tests in sensory diabetic neuropathy. Clin. Auton. Res. 8:1998;213-220.
13. Kihara M., Nakashima H., Takahashi M., Kawamura Y. A dysautonomia case of Guillain-Barre syndrome with recovery: monitored by composite autonomic scoring scale. J. Auton. Nerv. Syst. 72:1998;186-189.
14. Kihara M., Nakashima H., Taki M., Takahashi M., Kawamura Y. A case of chorea-acanthocytosis with dysautonomia; quantitative autonomic deficits using CASS. Auton. Nurosci. 97:2002;42-44.
15. Waterman S.A. Autonomic dysfunction in Lambert-Eaton myasthenic syndrome. Clin. Auton. Res. 11:2001;145-154.
16. O'Suilleabhain P., Low P.A., Lennon V.A. Autonomic dysfunction in Lambert-Eaton myasthenic syndrome. Neurology. 50:1998;88-93.
17. McEvoy K.M., Windebank A.J., Daube J.R., Low P.A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N. Engl. J. Med. 321:1989;1567-1571.
18. O'Neill J.H., Murray N.M., Newson-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain. 111:1988;577-596.
19. Lennon V.A., Kryzer T.J., Griesmann G.E. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndrome. N. Engl. J. Med. 332:1995;1467-1474.
20. Motomura M., Lang B., Joh I. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 147:1997;35-42.
21. Peers C., Johston I., Lang B. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Neurosci. Lett. 153:1993;45-48.
22. Martin-Moutot N., Lang B., Newsom-Davis J. Binding of Lambert-Eaton myasthenic syndrome IgG to synaptosomal protein dose not correlate with an inhibition of calcium uptake. Neurosci. Lett. 187:1995;115-118.
23. Lundy P.M., Frew R. Effect of ω-agatoxin-IVA on autonomic neurotransmission. Eur. J. Pharmacol. 261:1994;79-84.
24. 2+ channels in evoked release of norepinephrine from sympathetic neurons. Science. 239:1988;57-60.
25. Rubin D.I., Daube J.R. Subacute sensory neuropathy associated with Epstein-Barr virus. Muscle Nerve. 22:1999;1607-1610.
26. Corssmit E.P.M., Leverstein-van Hall M.A., Protegies P., Bakker P. Severe neurological complications in association with Epstein-Barr virus infection. J. Neurovirol. 3:1977;460-464.
27. Grose C., Henle W., Henle G., Feorino P.M. Primary Epstein-Barr virus infections in acute neurological disease. N. Engl. J. Med. 292:1975;392-395.
28. Junker A.K., Roland E.H., Hahn G. Transverse myelitis and Epstein-Barr virus infection with delayed antibody response. Neurology. 41:1991;1523-1524.
29. Davie J.C., Ceballos R. Infectious mononucleosis with fatal neuritis. Arch. Neurol. 9:1963;71-78.
30. Liveson J.A., Googgold J. Mononeuritis multiplex associated with infectious mononucleosis. Can. J. Neurol. Sci. 1:1974;203-205.
31. Garin C., Langan Y., Hutchinson M. Cranial and peripheral neuropathy due to Epstein-Barr virus infection. Postgrad. Med. J. 73:1997;429-433.
32. Mohanaruban K., Fisher D.J.H. A combination of cranial and peripheral nerve paralysis in infectious mononucleosis. Postgrad. Med. J. 62:1986;1129-1130.
33. Sharma K.R., Sriram S., Fries T., Bevan H.J., Bradley W.G. Lumbosacral radiculoplexopathy as a manifestation of Epstein-Barr virus infection. Neurology. 43:1993;2550-2554.
34. Junker A.K. Epstein-Barr virus disease. McKendell R.R., Stroop W.G. Handbook of Neurovirology. 1994;297-305 Marcel Dekker, New York.
35. López-Navidad A., Domingo P., López-Talavera J.C., Rabella N., Verger G. Epstein-Barr virus infection associated with interstitial nephritis and chronic fatigue. Scand. J. Infect. Dis. 28:1996;185-187.